Mostrando 10 resultados de: 10
Filtros aplicados
Publisher
Cell and Bioscience(2)
Expert Opinion on Drug Discovery(2)
Current Neuropharmacology(1)
Current Pharmaceutical Design(1)
Journal of Alzheimer's Disease(1)
Área temáticas
Enfermedades(8)
Farmacología y terapéutica(8)
Fisiología humana(4)
Medicina y salud(3)
Ginecología, obstetricia, pediatría, geriatría(2)
Área de conocimiento
Neurología(3)
Nanopartícula(2)
Descubrimiento de fármacos(1)
Medicamento(1)
Neuropsicología(1)
Origen
scopus(10)
Antiapoptotic drugs: A therapautic strategy for the prevention of neurodegenerative diseases
ReviewAbstract: The purpose of this review is to discuss potential pathways involved in the pathogenesis of neurodegPalabras claves:Alzheimer's disease, apoptosis, Cyclin-dependent kinases, Glutamate receptors, Neuronal cell death, Neuroprotective drugs. apoptosis, Parkinson's DiseaseAutores:Antoni Camins, Auladell C., Canudas A.M., Folch J., Junyent F., Pallás M., Pelegrí Gabalda C., Sureda F.X., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusA novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusAging biology: A new frontier for drug discovery
ReviewAbstract: Introduction: The prevalence of age-related pathologies, such as cardiovascular disease, neurodegenePalabras claves:Autores:Antoni Camins, Auladell C., Folch J., Junyent F., Pallás M., Verdaguer E., Zárate C.B.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusExperimental models for aging and their potential for novel drug discovery
ReviewAbstract: Background: An interesting area of scientific research is the development of potential antiaging druPalabras claves:aging, Heterogeneous mice model, IGF-1, mTOR, Resveratrol, SAMP8, SirtuinsAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Ettcheto M., Folch J., Miguel Marin, Olloquequi J., Pallás M., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusPharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease
ReviewAbstract: To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concepPalabras claves:BDNF, dendritic spines, late onset Alzheimer's disease, neuroinflammation, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Casadesús G., Castro-Torres R.D., Espinosa-Jimenez T., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Sureda F.X., Verdaguer E.Fuentes:scopusPrevention of epilepsy by taurine treatments in mice experimental model
ArticleAbstract: An experimental model based on kainic acid (KA) injections replicates many phenomenological featuresPalabras claves:Kainic acid, Neurodegeneration, neuroprotectionAutores:Antoni Camins, Auladell C., Duque D., Junyent F., Pallás M., Romero R., Utrera J.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus